Business Context and Reporting Period
This Form 8-K Current Report was filed by IDEAYA Biosciences, Inc. on April 7, 2020, covering events occurring on April 6, 2020. The Company is a Delaware corporation listed on The Nasdaq Global Select Market under the symbol IDYA and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of a senior executive:
- Departure: Julie Hambleton, M.D., is retiring as Senior Vice President and Chief Medical Officer, Head of Development.
- Effective Date: Her employment will end on April 30, 2020.
- Transition Plan: A Separation Agreement and a Consulting Agreement were executed on April 6, 2020.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or general management commentary regarding business operations. The document details the terms of the executive separation:
- Compensation: Dr. Hambleton will receive salary continuation for 2 months as a separation benefit.
- Offset: This benefit is offset by any consulting fees paid for services rendered between May and June 2020.
- Consulting Role: She will provide limited consulting services from May 1, 2020, to June 30, 2020.
- Covenants: The agreement includes confidentiality, non-disparagement, non-solicitation, and a release of claims.
Investor Verification Checklist
- Verify the full text of the Separation Agreement and Consulting Agreement when filed as exhibits to the Form 10-Q for the quarter ending June 30, 2020.
- Confirm the appointment of a successor to the Chief Medical Officer role to assess potential impacts on development timelines.
- Review the Company's upcoming quarterly report for any financial impact related to the separation benefits.